School of Medicine, Marsico Lung Institute, UNC Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Department of Pulmonology, Division of Pulmonary and Critical Care Medicine, School of Medicine, The University of Kansas, Kansas City, Kansas, United States of America.
PLoS One. 2018 Oct 11;13(10):e0205257. doi: 10.1371/journal.pone.0205257. eCollection 2018.
Previous reports of lung function in cystic fibrosis (CF) patients with liver disease have shown worse, similar, or even better forced expiratory volume in 1 second (FEV1), compared to CF patients without liver disease. Varying definitions of CF liver disease likely contribute to these inconsistent relationships reported between CF lung function and liver disease. We retrospectively evaluated spirometric data in 179 subjects (62% male; 58% Phe508del homozygous) with severe CF liver disease (CFLD; defined by presence of portal hypertension due to cirrhosis). FEV1 values were referenced to both a normal population (FEV1% predicted) and CF population (CF-specific FEV1 percentile). We utilized a linear mixed model with repeated measures to assess changes in lung function (before and after diagnosis of CFLD), relative to both the normal and CF populations. At diagnosis of CFLD, the mean FEV1 was 81% predicted, or at the 53rd percentile referenced to CF patients without CFLD. There was a significant difference in post-CFLD slope compared to pre-CFLD slope (post-pre) using FEV1% predicted (-1.94, p-value < 0.0001). However, there was insignificant evidence of this difference using the CF-specific FEV1 percentile measure (-0.99, p-value = 0.1268). Although FEV1% predicted values declined in patients following CFLD diagnosis, there was not significant evidence of lung function decline in CF-specific FEV1 percentiles. Thus, the observed study cohort indicates diagnosis of severe CFLD was not associated with worsened CF lung disease when compared to a large CF reference population.
先前关于患有肝病的囊性纤维化 (CF) 患者的肺功能报告显示,与无肝病的 CF 患者相比,其 1 秒用力呼气量 (FEV1) 更差、相似甚至更好。CF 肝病的不同定义可能导致 CF 肺功能与肝病之间报告的这些不一致关系。我们回顾性评估了 179 例严重 CF 肝病 (CFLD;定义为肝硬化引起的门静脉高压) 患者的肺功能数据 (62%为男性;58%为纯合子 Phe508del)。FEV1 值参考正常人群 (FEV1%预测值) 和 CF 人群 (CF 特有的 FEV1 百分位数)。我们使用具有重复测量的线性混合模型来评估肺功能的变化 (在诊断 CFLD 之前和之后),相对于正常人群和 CF 人群。在诊断为 CFLD 时,FEV1 的平均值为预测值的 81%,或在无 CFLD 的 CF 患者中参考 CF 特有的 FEV1 百分位数为第 53 百分位。与 CFLD 前斜率相比,CFLD 后斜率 (后-前) 有显著差异,使用 FEV1%预测值 (-1.94,p 值 < 0.0001)。然而,使用 CF 特有的 FEV1 百分位数测量值则没有这种差异的证据 (-0.99,p 值 = 0.1268)。尽管在 CFLD 诊断后 FEV1%预测值下降,但 CF 特有的 FEV1 百分位数并没有显著证据表明肺功能下降。因此,观察到的研究队列表明,与大型 CF 参考人群相比,严重 CFLD 的诊断与 CF 肺部疾病的恶化无关。